摘要
目的 :探讨不同剂量的氟伐他汀 (来适可 )治疗急性冠脉综合征 (ACS)患者血脂异常 6个月的疗效及安全性。方法 :回顾性分析 2 31例ACS病人资料 ,共分为三组 ,A组 5 1例未服用来适可 ,B组 99例口服来适可 2 0mg ,每晚一次 ,C组 81例口服来适可 4 0mg ,每晚一次。均没有服用其他降脂药物 ,基础血脂为发病 2 4h以内的血脂 ,随访半年 ,观察血脂 (TC、LDL -C、HDL -C、TG)的变化及不良反应。结果 :B、C两组降脂作用方面与A组比较有显著差异 (P <0 .0 1 ) ,C组优于B组 (P <0 .0 1 )。不良反应三组无显著性差异 (P >0 .0 5 )。结论 :来适可明显降低ACS患者中TC、LDL -C ,并能明显升高HDL -C ,且有剂量依赖性 ,不良反应少 。
Objective: The study aims to research for the lowering-lipid effect and safety of different dosage Fluvastatin(lescol) in ACS .Method:231 patients were divided into three groups(no lescol group,20mg/d dosage group and 40mg/d dosage group)and Blood lipids were followed up for 24 weeks .Result:Lescol has a stronger lowering-lipid action in 20mg/d and 40mg/d dosage groups than no lescol group and 40mg/d dosage group is superior to 20mg/d dosage group ,but the harmful actions are similar in three groups. Conclusion:Lescol lowers obviously the level of total cholesterol and low-density-lipoprotein and raise high-density-lipoprotein ,the lowering-lipid action is correlated with lescol dosage and also safe.
出处
《河北医学》
CAS
2003年第8期714-716,共3页
Hebei Medicine
